Pharmaceutical Lipids Market by Product Type (Cholesterol, Fatty Acids, Triglycerides, Phospholipids, Sphingolipids, Others) by Form (Solid, Semi-Solid, Liquid) by Source (Natural, Synthetic, Semi-Synthetic) by Application (Solid Lipid Nanoparticles, Self-Emulsifying Drug Delivery Systems (SEDDS), Self-Microemulsifying Drug Delivery Systems (SMEDDS), Conventional Lipid-Based Drug Delivery Systems (LBDDS), Nanostructured Lipid Carriers, Liposomes, Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 23-Mar-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-6008 Status : Published

The pharmaceutical lipids market is set for a rapid growth over the forecast period. In terms of revenue, the global pharmaceutical lipids market accounted for USD 2,226.02 Million in 2019 and is expected to reach USD 3,279.85 Million by 2026, growing at a CAGR of 5.69%.

Description

The pharmaceutical lipids market is set for a rapid growth over the forecast period. In terms of revenue, the global pharmaceutical lipids market accounted for USD 2,226.02 Million in 2019 and is expected to reach USD 3,279.85 Million by 2026, growing at a CAGR of 5.69%.

Global Pharmaceutical Lipids Market: Overview

Lipids perform essential roles in a number of contexts. They are vital for all living things because they perform important plastic, energy, and metabolic functions. They also have various uses in nutrition and dietetics, food science, cosmetics, pharmaceuticals, varnishes, detergents, paints and so on. According to the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization, the five major functions of dietary fats are as follows: for cell structure and membrane functions, as a source of energy obtaining mainly water and carbon dioxide in their final conversion, as a source of essential fatty acids for prostaglandin synthesis and cell structures, as a medium for oil-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K,  and for blood lipid regulation. Fats have a long and contentious history in relation to cholesterol metabolism and cardiovascular disease (coronary thrombosis, atherosclerosis, and cerebral haemorrhage). Many concerns regarding the roles of fats in these phenomena in relation to the structures of dietary fatty acids remain unanswered. Many recent advances have been made in complexes where lipids and proteins are held together by van der Waal forces, like in lipoproteins. Now it appears that there is a close association between the occurrence of blood levels of High-Density Lipoproteins (HDL) and cardiovascular disease, or the ratio of high to low density lipoproteins.

Global Pharmaceutical Lipids Market

Global Pharmaceutical Lipids Market: Growth Factors

The global healthcare industry has undergone significant changes in recent years. The advancement of drug delivery technology, as well as the implementation of drug formularies, is driving the growth of the pharmaceutical lipids market. One of the main factors driving the growth of the global pharmaceutical lipids market is the rapid onset of chronic health problems and the subsequent drug delivery to patients.

According to the American Association of Pharmaceutical Scientists (AAPS), approximately 90% of pipeline drugs and 40% of marketed drugs have low water solubility. Based on this assumption, lipid-based formulations are becoming more common in nutraceuticals, vaccines, diagnostics, and pharmaceuticals. This is projected to be a significant growth driver for the market.

Moreover, lipid-based formulations protect active compounds from degradation, or biological transformation, thereby increasing drug production and shelf life. Furthermore, lipid-based particulate drug delivery system changes biodistribution and, as a result, decreases the level of toxicity in a number of medications. This raises the safety index, accelerating market growth.

Because of the increased demand for lipid nanocarriers due to their improved biocompatibility, market participants are moving away from polymeric nanoparticles towards the former. This is expected to generate lucrative business opportunities in the coming years.

The outbreak of Covid-19 has increased competition for pharmaceutical lipids along with other medications. This is because healthcare workers and researchers around the world are looking for ways to tackle Covid-19. For instance, in May 2020, Moderna Inc. announced its agreement with CordenPharma to secure large quantities of lipids used in the production of its experimental Covid-19 vaccine. Moderna also announced that if the vaccine is effective, it plans to supply one million doses per month in 2020 and 10 million doses per month in 2021. According to researchers at Hebrew University (Israel), fenofibrate, an existing cholesterol medication, is capable of reducing the danger posed by Covid-19 to common cold.

Global Pharmaceutical Lipids Market: Segmentation

Lipids are vital biomolecules. For instance, cholesterol is a critical component of the human cell membrane as well as a precursor of bile acids and steroid hormones. Moreover, Triglycerides also play a critical role in the transfer of energy from food to body cells. However, any biomolecule in abundance is detrimental to human health. Similarly, an increase in various types of lipids in the bloodstream, known as hyperlipidemia, is a constant health problem. Since lipids are held in the bloodstream, hyperlipidemia is often a danger to coronary arteries and the most significant risk factor for coronary heart disease.

However, in order to combat these issues, a number of medications known as lipid-lowering drugs are developed. Statins are a class of drugs that lower cholesterol by interacting with the cholesterol biosynthetic pathway. Fibrates, on the other hand, lower fatty acid and triglyceride levels by activating the peroxisomal β-oxidation pathway.

Global Pharmaceutical Lipids Market: Regional Analysis

By Geography, the pharmaceutical lipids market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East and Africa.

Asia Pacific is the most lucrative market for pharmaceutical lipids due of the high rate of adoption of proprietary drugs. Increased acceptance of generic drugs and branded generic in Asia-Pacific will drive the lipids active pharmaceutical ingredients market to exponential growth in the near future. However, the FDA's stringent regulatory environment for the approval of drugs containing lipid active pharmaceutical ingredients would restrict the market's growth. The pharmaceutical lipids market in Asia-Pacific is dominated by India, Japan, and China. South Asia is a promising market due to growth in in-house production.

North America is also seeing an increase in the market for long-acting formulations. Increased cases of various deadly diseases are expected to fuel the demand during the forecast era. The market for lipophilic drugs in Europe, on the other hand, is driven by better bioavailability. An increasing number of healthcare centers and growing demand for medical formulations are expected to drive the market in Europe.

Global Pharmaceutical Lipids Market: Competitive Players

The major players in the global pharmaceutical lipids market include Merck KGaA, BASF SE, Avanti Polar Lipids Inc., Corden Pharma International, Cayman Chemical Company, NOF Corporation, Stepan Company, and Croda International Plc among others.

The report segment of global pharmaceutical lipids market are as follows:

Global Pharmaceutical Lipids Market: Product Type Segment Analysis

  • Cholesterol
  • Fatty Acids
  • Phospholipids
  • Sphingolipids
  • Others

Global Pharmaceutical Lipids Market: Form Segment Analysis

  • Solid
  • Semi-Solid
  • Liquid

Global Pharmaceutical Lipids Market: Source Segment Analysis

  • Natural
  • Synthetic
  • Semi-Synthetic

Global Pharmaceutical Lipids Market: Application Segment Analysis

  • Solid Lipid Nanoparticles
  • Self-Emulsifying Drug Delivery Systems (SEDDS)
  • Self-Microemulsifying Drug Delivery Systems (SMEDDS)
  • Conventional Lipid-Based Drug Delivery Systems (LBDDS)
  • Nanostructured Lipid Carriers
  • Liposomes
  • Others

Global Pharmaceutical Lipids Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description
      • 1.1.1. Objective
      • 1.1.2. Target Audience
      • 1.1.3. Unique Selling Proposition (USP) & Offerings
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
      • 1.3.3. Level 1: Primary Research
      • 1.3.4. Level 2: Secondary Research
      • 1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope
  • Chapter 2. Executive Summary
    • 2.1. Global Pharmaceutical Lipids Market, 2016-2026, (USD Million)
    • 2.2. Pharmaceutical Lipids Market: Market Snapshot
  • Chapter 3. Global Pharmaceutical Lipids Market – Industry Analysis
    • 3.1. Introduction
    • 3.2. Industry Ecosystem Analysis
    • 3.3. Technulogy Landscape
    • 3.4. Market Drivers
      • 3.4.1. North America
      • 3.4.2. Europe
      • 3.4.3. Asia Pacific
      • 3.4.4. Latin America
      • 3.4.5. MEA
    • 3.5. Restraints
    • 3.6. Opportunity
    • 3.7. Innovation & Sustainability
    • 3.8. Regulatory Landscape
    • 3.9. Porter’s Five Forces Analysis
    • 3.10. PESTLE Analysis
    • 3.11. Pharmaceutical Lipids Market: Market Attractiveness Analysis
      • 3.11.1. Market Attractiveness Analysis by Product Type Segment
      • 3.11.2. Market Attractiveness Analysis by Form Segment
      • 3.11.3. Market Attractiveness Analysis by Source Segment
      • 3.11.4. Market Attractiveness Analysis by Application Segment
  • Chapter 4. Global Pharmaceutical Lipids Market - Competitive Landscape
    • 4.1. Company Market Share Analysis, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions and Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
      • 4.2.4. Research & Development and Regional Expansion
  • Chapter 5. Pharmaceutical Lipids Market – Product Type Segment Analysis
    • 5.1. Global Pharmaceutical Lipids Market Revenue Share, by Product Type, 2019 & 2026 (USD Million)
    • 5.2. Global Pharmaceutical Lipids Market by Chulesterul, 2016 – 2026 (USD Million)
    • 5.3. Global Pharmaceutical Lipids Market by Fatty Acids, 2016 – 2026 (USD Million)
    • 5.4. Global Pharmaceutical Lipids Market by Triglycerides, 2016 – 2026 (USD Million)
    • 5.5. Global Pharmaceutical Lipids Market by Phosphulipids, 2016 – 2026 (USD Million)
    • 5.6. Global Pharmaceutical Lipids Market by Sphingulipids, 2016 – 2026 (USD Million)
    • 5.7. Global Pharmaceutical Lipids Market by Others, 2016 – 2026 (USD Million)
  • Chapter 6. Pharmaceutical Lipids Market – Form Segment Analysis
    • 6.1. Global Pharmaceutical Lipids Market Revenue Share, by Form, 2019 & 2026 (USD Million)
    • 6.2. Global Pharmaceutical Lipids Market by Sulid, 2016 – 2026 (USD Million)
    • 6.3. Global Pharmaceutical Lipids Market by Semi-Sulid, 2016 – 2026 (USD Million)
    • 6.4. Global Pharmaceutical Lipids Market by Liquid, 2016 – 2026 (USD Million)
  • Chapter 7. Pharmaceutical Lipids Market – Source Segment Analysis
    • 7.1. Global Pharmaceutical Lipids Market Revenue Share, by Source, 2019 & 2026 (USD Million)
    • 7.2. Global Pharmaceutical Lipids Market by Natural, 2016 – 2026 (USD Million)
    • 7.3. Global Pharmaceutical Lipids Market by Synthetic, 2016 – 2026 (USD Million)
    • 7.4. Global Pharmaceutical Lipids Market by Semi-Synthetic, 2016 – 2026 (USD Million)
  • Chapter 8. Pharmaceutical Lipids Market – Application Segment Analysis
    • 8.1. Global Pharmaceutical Lipids Market Revenue Share, by Application, 2019 & 2026 (USD Million)
    • 8.2. Global Pharmaceutical Lipids Market by Sulid Lipid Nanoparticles, 2016 – 2026 (USD Million)
    • 8.3. Global Pharmaceutical Lipids Market by Self-Emulsifying Drug Delivery Systems (SEDDS), 2016 – 2026 (USD Million)
    • 8.4. Global Pharmaceutical Lipids Market by Self-Microemulsifying Drug Delivery Systems (SMEDDS), 2016 – 2026 (USD Million)
    • 8.5. Global Pharmaceutical Lipids Market by Conventional Lipid-Based Drug Delivery Systems (LBDDS), 2016 – 2026 (USD Million)
    • 8.6. Global Pharmaceutical Lipids Market by Nanostructured Lipid Carriers, 2016 – 2026 (USD Million)
    • 8.7. Global Pharmaceutical Lipids Market by Liposomes, 2016 – 2026 (USD Million)
    • 8.8. Global Pharmaceutical Lipids Market by Others, 2016 – 2026 (USD Million)
  • Chapter 9. Pharmaceutical Lipids Market - Regional Analysis
    • 9.1. Global Pharmaceutical Lipids Market: Regional Overview
      • 9.1.1. Global Pharmaceutical Lipids Market Revenue Share, By Region, 2019 & 2026 (USD Million)
    • 9.2. North America
      • 9.2.1. North America Pharmaceutical Lipids Market Revenue 2016 – 2026 (USD Million)
      • 9.2.2. North America Pharmaceutical Lipids Market Revenue, By Product Type, 2016 – 2026 (USD Million)
      • 9.2.3. North America Pharmaceutical Lipids Market Revenue, By Form, 2016 – 2026 (USD Million)
      • 9.2.4. North America Pharmaceutical Lipids Market Revenue, By Source, 2016 – 2026 (USD Million)
      • 9.2.5. North America Pharmaceutical Lipids Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.2.6. U.S.
        • 9.2.6.1. U.S. Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.2.6.2. U.S. Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.2.6.3. U.S. Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.2.6.4. U.S. Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.2.7. Canada
        • 9.2.7.1. Canada Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.2.7.2. Canada Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.2.7.3. Canada Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.2.7.4. Canada Education & Learning Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.2.8. Mexico
        • 9.2.8.1. Mexico Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.2.8.2. Mexico Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.2.8.3. Mexico Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.2.8.4. Mexico Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Pharmaceutical Lipids Market Revenue 2016 – 2026 (USD Million)
      • 9.3.2. Europe Pharmaceutical Lipids Market Revenue, By Product Type, 2016 – 2026 (USD Million)
      • 9.3.3. Europe Pharmaceutical Lipids Market Revenue, By Form, 2016 – 2026 (USD Million)
      • 9.3.4. Europe Pharmaceutical Lipids Market Revenue, By Source, 2016 – 2026 (USD Million)
      • 9.3.5. Europe Pharmaceutical Lipids Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.3.6. UK
        • 9.3.6.1. UK Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.6.2. UK Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.6.3. UK Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.6.4. UK Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.7.2. France Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.7.3. France Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.7.4. France Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.8. Germany
        • 9.3.8.1. Germany Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.8.2. Germany Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.8.3. Germany Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.8.4. Germany Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.9. Italy
        • 9.3.9.1. Italy Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.9.2. Italy Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.9.3. Italy Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.9.4. Italy Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.10. Spain
        • 9.3.10.1. Spain Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.10.2. Spain Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.10.3. Spain Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.10.4. Spain Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.11. Russia
        • 9.3.11.1. Russia Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.11.2. Russia Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.11.3. Russia Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.11.4. Russia Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.3.12. Rest of Europe
        • 9.3.12.1. Rest of Europe Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.3.12.2. Rest of Europe Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.3.12.3. Rest of Europe Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.3.12.4. Rest of Europe Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Pharmaceutical Lipids Market Revenue 2016 – 2026 (USD Million)
      • 9.4.2. Asia Pacific Pharmaceutical Lipids Market Revenue, By Product Type, 2016 – 2026 (USD Million)
      • 9.4.3. Asia Pacific Pharmaceutical Lipids Market Revenue, By Form, 2016 – 2026 (USD Million)
      • 9.4.4. Asia Pacific Pharmaceutical Lipids Market Revenue, By Source, 2016 – 2026 (USD Million)
      • 9.4.5. Asia Pacific Pharmaceutical Lipids Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.6.2. China Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.6.3. China Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.6.4. China Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.4.7. Japan
        • 9.4.7.1. Japan Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.7.2. Japan Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.7.3. Japan Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.7.4. Japan Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.8.2. India Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.8.3. India Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.8.4. India Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.4.9. Australia
        • 9.4.9.1. Australia Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.9.2. Australia Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.9.3. Australia Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.9.4. Australia Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.4.10. South Korea
        • 9.4.10.1. South Korea Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.10.2. South Korea Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.10.3. South Korea Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.10.4. South Korea Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.4.11. Rest of Asia Pacific
        • 9.4.11.1. Rest of Asia Pacific Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.4.11.2. Rest of Asia Pacific Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.4.11.3. Rest of Asia Pacific Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.4.11.4. Rest of Asia Pacific Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Pharmaceutical Lipids Market Revenue 2016 – 2026 (USD Million)
      • 9.5.2. Latin America Pharmaceutical Lipids Market Revenue, By Product Type, 2016 – 2026 (USD Million)
      • 9.5.3. Latin America Pharmaceutical Lipids Market Revenue, By Form, 2016 – 2026 (USD Million)
      • 9.5.4. Latin America Pharmaceutical Lipids Market Revenue, By Source, 2016 – 2026 (USD Million)
      • 9.5.5. Latin America Pharmaceutical Lipids Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.5.6.2. Brazil Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.5.6.3. Brazil Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.5.6.4. Brazil Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.5.7. Argentina
        • 9.5.7.1. Argentina Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.5.7.2. Argentina Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.5.7.3. Argentina Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.5.7.4. Argentina Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.5.8. Rest of Latin America
        • 9.5.8.1. Rest of Latin America Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.5.8.2. Rest of Latin America Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.5.8.3. Rest of Latin America Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.5.8.4. Rest of Latin America Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa Pharmaceutical Lipids Market Revenue 2016 – 2026 (USD Million)
      • 9.6.2. Middle East & Africa Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
      • 9.6.3. Middle East & Africa Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
      • 9.6.4. Middle East & Africa Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
      • 9.6.5. Middle East & Africa Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.6.6. GCC Countries
        • 9.6.6.1. GCC Countries Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.6.6.2. GCC Countries Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.6.6.3. GCC Countries Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.6.6.4. GCC Countries Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.6.7. South Africa
        • 9.6.7.1. South Africa Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.6.7.2. South Africa Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.6.7.3. South Africa Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.6.7.4. South Africa Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.6.8. Rest of MEA
        • 9.6.8.1. Rest of MEA Pharmaceutical Lipids Market Revenue, by Product Type, 2016 – 2026 (USD Million)
        • 9.6.8.2. Rest of MEA Pharmaceutical Lipids Market Revenue, by Form, 2016 – 2026 (USD Million)
        • 9.6.8.3. Rest of MEA Pharmaceutical Lipids Market Revenue, by Source, 2016 – 2026 (USD Million)
        • 9.6.8.4. Rest of MEA Pharmaceutical Lipids Market Revenue, by Application, 2016 – 2026 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1. Merck KGaA
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfulio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. *Same information will be provided for below mentioned companies*
      • 10.2.1. BASF SE
      • 10.2.2. Avanti Pular Lipids Inc.
      • 10.2.3. Corden Pharma International
      • 10.2.4. Cayman Chemical Company
      • 10.2.5. NOF Corporation
      • 10.2.6. Stepan Company
      • 10.2.7. Croda International Plc
      • 10.2.8. Others

Methodology


Frequently Asked Questions

The global healthcare industry has undergone significant changes in recent years. The advancement of drug delivery technology, as well as the implementation of drug formularies, is driving the growth of the pharmaceutical lipids market. One of the main factors driving the growth of the global pharmaceutical lipids market is the rapid onset of chronic health problems and the subsequent drug delivery to patients. According to the American Association of Pharmaceutical Scientists (AAPS), approximately 90% of pipeline drugs and 40% of marketed drugs have low water solubility. Based on this assumption, lipid-based formulations are becoming more common in nutraceuticals, vaccines, diagnostics, and pharmaceuticals. This is projected to be a significant growth driver for the market. Moreover, lipid-based formulations protect active compounds from degradation, or biological transformation, thereby increasing drug production and shelf life. Furthermore, lipid-based particulate drug delivery system changes biodistribution and, as a result, decreases the level of toxicity in a number of medications. This raises the safety index, accelerating market growth.

According to Zion Market Research, the Pharmaceutical Lipids market is expected to generate revenue of around USD 3,279.85 Million by the end of 2026, growing at a CAGR of 5.69%.

Asia Pacific is the most lucrative market for pharmaceutical lipids due of the high rate of adoption of proprietary drugs. Increased acceptance of generic drugs and branded generic in Asia-Pacific will drive the lipids active pharmaceutical ingredients market to exponential growth in the near future. However, the FDA's stringent regulatory environment for the approval of drugs containing lipid active pharmaceutical ingredients would restrict the market's growth. The pharmaceutical lipids market in Asia-Pacific is dominated by India, Japan, and China. South Asia is a promising market due to growth in in-house production.

The major players in the global pharmaceutical lipids market include Merck KGaA, BASF SE, Avanti Polar Lipids Inc., Corden Pharma International, Cayman Chemical Company, NOF Corporation, Stepan Company, and Croda International Plc among others.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com